# Clinical Trial: An App to Reduce Cannabis Use Among Emerging Adults > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ced-sex-differences-targeted-therapeutics-and-dig-2026-10-27/ > **Published:** 2026-10-27T11:18:56-04:00 | **Last Modified / Clinically Audited:** 2026-10-27T11:18:56-04:00 > **Clinical Summary:** cannabis news digest: CED Clinic analysis of 3 recent cannabis policy, science, and regulatory developments with Dr. Benjamin Caplan. --- CED Clinical Relevance #65 Verified Overview Curated multi-source overview preserving 3 verified developments. Clinical Insight | CED Clinic Clinical practice requires addressing both biological mechanisms and patient behaviors. Sex-specific differences in cannabinoid metabolism and receptor sensitivity affect baseline sensitivity, pain response, and tolerance development. When patients attempt to reduce or discontinue daily consumption, unmanaged withdrawal symptoms like sleep disruption, anxiety, and irritability frequently precipitate relapse. Synthetic cannabinoid receptor agonists like nabilone or novel agents like PP-01 aim to blunt these neurobiological surges, while mobile behavioral tools address daily triggers and habits. Integrating biological dosing precision with targeted cessation support forms a rational pathway for patient management. DigestCannabis NewsRegulationPublic HealthClinical Practice AudiencePatients, clinicians, healthcare professionals, regulators, and industry researchers. Primary TopicClinical and policy analysis: Clinical Trial: An App to Reduce Cannabis Use Among Eme. Source[Read the full source](https://clinicaltrials.gov/study/NCT04385082) Table of Contents - [Clinical Trial: An App to Reduce Cannabis Use Among Emerging Adults](#Clinical_Trial_An_App_to_Reduce_Cannabis_Use_Among_Emerging_Adults)[How to Interpret This Cannabis News & Regulatory Digest](#How_to_Interpret_This_Cannabis_News_Regulatory_Digest)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading) - [CED Perspective Lens: Eight Viewpoints on These Updates](#CED_Perspective_Lens_Eight_Viewpoints_on_These_Updates)[Understanding Individual Biological Factors and Support Tools](#Understanding_Individual_Biological_Factors_and_Support_Tools) - [Translating Sex-Specific Dosing and Withdrawal Protocols](#Translating_Sex-Specific_Dosing_and_Withdrawal_Protocols) - [Prioritizing Biological Precision and Withdrawal Risk Mitigation](#Prioritizing_Biological_Precision_and_Withdrawal_Risk_Mitigation) - [Aligning Clinical Evidence with Regulatory Frameworks](#Aligning_Clinical_Evidence_with_Regulatory_Frameworks) - [Advancing Methodological Rigor in Cannabinoid Trials](#Advancing_Methodological_Rigor_in_Cannabinoid_Trials) - [Evaluating Methodological Limits and Data Applicability](#Evaluating_Methodological_Limits_and_Data_Applicability) - [Supporting Family Members Through Treatment and Cessation](#Supporting_Family_Members_Through_Treatment_and_Cessation) - [Integrating Biological Stratification and Comprehensive Cessation Care](#Integrating_Biological_Stratification_and_Comprehensive_Cessation_Care) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) # Clinical Trial: An App to Reduce Cannabis Use Among Emerging Adults A structured CED Clinic overview of 3 key developments in cannabis regulation, market milestones, and scientific research. What This Study Teaches Us Recent registry updates outline a completed UCLA Phase 1 trial investigating sex differences in pain relief and abuse liability, a recruiting Phase 3 trial testing PP-01 against nabilone and placebo for withdrawal in moderate to severe cannabis use disorder, and a completed University of Michigan pilot examining a mobile app to curb high-risk consumption in emerging adults. The PP-01 Phase 3 study evaluates symptom mitigation during forced abstinence across multi-center sites, while the Michigan digital intervention targets behavior modification through self-directed smartphone tools. Why This Matters Biological differences between men and women influence cannabinoid pharmacodynamics, requiring sex-specific dosing frameworks to optimize pain relief while minimizing side effects. Concurrently, formalizing pharmaceutical and digital support structures gives clinicians validated tools for patients struggling with cessation or withdrawal. Study SnapshotPost TypeCannabis News & Regulatory Digest using canonical CED layoutItems Reviewed3 verified updatesPrimary DatesOctober 27, 2026Related Reading3 verified live CED Clinic internal linksUpdate 1Cannabis Effects as a Function (University of California, Los Angeles Regulatory Analysis)Update 2Efficacy of PP-01 in Mitigating (PleoPharma, Inc. Regulatory Analysis)Update 3An App to Reduce Cannabis (University of Michigan Regulatory Analysis) Clinical Bottom Line This clinical and regulatory overview preserves key signals across 3 updates without overstatement, offering grounded guidance for patients and practitioners. Context Across These 3 Updates This curated cannabis news & regulatory digest brings together 3 key developments across policy movements, regulatory milestones, and public health communications. Reviewing these distinct updates side by side clarifies emerging patterns while preserving the specific clinical context of each report. Examining these developments concurrently helps clinicians, patients, and families trace the broader trajectory of the field while grounding practical decisions in verified primary data. Update 1: Cannabis Effects as a Function of Sex **Title & Source:** [Clinical Trial: Cannabis Effects as a Function of Sex](https://clinicaltrials.gov/study/NCT04385082) (*University of California, Los Angeles*, 2026-10-27) **Lead Authors & Identifiers:** University of California, Los Angeles. Content lane: **Clinical Evidence Update**. **Regulatory Context:** This completed Phase 1 human laboratory study conducted by UCLA investigated how biological sex alters acute analgesic responses and abuse-related effects of cannabis. The trial evaluated healthy adult volunteers in controlled laboratory settings to identify sex-dependent pharmacodynamic differences. **Operative Findings:** The study protocol systematically measured pain threshold changes and subjective abuse liability metrics following acute cannabinoid administration. Quantitative outcomes map distinct physiological and subjective response curves between male and female participants. **Clinical Relevance:** Clinicians should consider biological sex when initiating cannabinoid therapy, starting with lower doses for individuals who demonstrate higher baseline sensitivity. Adjusting titration schedules based on sex-specific responses optimizes therapeutic outcomes while minimizing unwanted side effects. **Practical Boundaries:** Small sample sizes inherent to Phase 1 laboratory designs limit the direct application of findings to chronic therapeutic consumers with complex health conditions. Update 2: Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms **Title & Source:** [Clinical Trial: Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder](https://clinicaltrials.gov/study/NCT07644052) (*PleoPharma, Inc.*, 2026-10-27) **Lead Authors & Identifiers:** PleoPharma, Inc.. Content lane: **Protocol Watch**. **Regulatory Context:** This recruiting Phase 3 randomized, double-blind, multi-center trial sponsored by PleoPharma tests PP-01 against nabilone and placebo for mitigating cannabis withdrawal symptoms. The study focuses on adult participants diagnosed with moderate to severe cannabis use disorder who undergo structured cessation. **Operative Findings:** The trial evaluates quantitative reductions in validated withdrawal score indices, mood scales, and retention rates across the three treatment arms. Initial protocols establish controlled administration during acute abstinence to isolate therapeutic efficacy. **Clinical Relevance:** Prescribers should monitor patients undergoing cannabis cessation for severe withdrawal symptoms that threaten recovery efforts. Pharmacological options like synthetic agonists provide structured medical support during the initial abstinence window. **Practical Boundaries:** Strict inclusion criteria may exclude patients with psychiatric co-morbidities or poly-substance use, narrowing generalizability across broader clinical populations. Update 3: An App to Reduce Cannabis Use Among Emerging **Title & Source:** [Clinical Trial: An App to Reduce Cannabis Use Among Emerging Adults](https://clinicaltrials.gov/study/NCT05824754) (*University of Michigan*, 2026-10-27) **Lead Authors & Identifiers:** University of Michigan. Content lane: **Clinical Evidence Update**. **Regulatory Context:** This completed pilot trial led by the University of Michigan evaluated a custom smartphone application designed to reduce high-risk cannabis consumption among emerging adults. The intervention tested mobile wellness delivery frameworks to encourage safer behaviors in young app users. **Operative Findings:** Results assessed app engagement metrics, daily logging completion rates, and self-reported reductions in risky cannabis consumption patterns. Primary endpoints established feasibility and positive user acceptability among young adult participants. **Clinical Relevance:** Digital self-monitoring tools offer accessible options for young adults seeking to moderate their cannabis intake. Recommending validated mobile tracking applications provides continuous behavioral feedback between clinical visits. **Practical Boundaries:** Self-reported usage data and short pilot intervention windows restrict definitive conclusions regarding long-term behavioral maintenance. How Strong Is This Evidence? The evidence spans early-phase mechanistic research to late-stage trials. Phase 1 human laboratory studies provide controlled physiological data on sex-dependent pharmacokinetics, while randomized Phase 3 protocols offer clinical rigor necessary to evaluate withdrawal interventions against established controls. Early-stage digital pilot trials offer initial feasibility metrics, though larger randomized trials are needed to confirm behavioral outcomes. Where This Paper Deserves Skepticism Phase 1 laboratory evaluations rely on small healthy cohorts under controlled acute exposures, which may not translate to chronic real-world therapeutic use. Digital health pilot studies frequently suffer from selection bias, high attrition rates, and brief follow-up windows that fail to capture long-term relapse patterns. Pharmaceutical withdrawal trials require careful monitoring to distinguish genuine symptom reduction from secondary cannabinoid toxicity or residual drug effects. What This Paper Does Not Show These trials do not establish universal sex-based dosing guidelines for commercial plant-derived cannabis products. They also do not prove that mobile software interventions alone yield long-term abstinence without concurrent medical or psychological supervision. How This Fits With the Broader Clinical Conversation The medical cannabis field is shifting toward granular patient stratification and structured cessation therapies. Early cannabis research treated patient populations as monolithic, overlooking fundamental biological variables like sex-dependent endocannabinoid tone and adipose tissue distribution. Modern research frameworks explicitly isolate these variables to determine how sex hormones alter CB1 receptor density and metabolic clearance. At the same time, the recognition of cannabis use disorder has spurred investment in pharmacological and digital therapeutic options. Synthetic cannabinoid receptor agonists and novel agents aim to ease acute neurochemical withdrawal, mirroring success seen in nicotine replacement therapies. Combining pharmacotherapy with digital health applications creates a multi-layered model capable of supporting patients across acute physical withdrawal and long-term behavioral maintenance. Editorial Commentary *In everyday clinical care, optimizing treatment requires balancing individualized therapeutic relief with practical safety protocols. Patients often report distinctly different experiences with identical cannabinoid formulations based on sex, body composition, and baseline receptor sensitivity. Recognizing that women may experience different analgesic thresholds or side effect profiles compared to men allows clinicians to refine initial dose titration protocols thoughtfully.* *Cessation management presents its own distinct set of challenges. Patients attempting to reduce daily intake often face sleep disturbances, night sweats, and mood swings that make unassisted withdrawal difficult. Having standardized pharmaceutical options alongside user-friendly digital tools gives clinicians a realistic, non-judgmental framework to assist individuals seeking to alter their daily cannabis relationship.* What a Careful Reader Should Take Away Clinicians should tailor cannabinoid dosing schedules with sex-specific sensitivity in mind while utilizing validated digital tools and structured therapeutic tapering when assisting patients with withdrawal or reduction goals. [https://cedclinic.com/ask](https://cedclinic.com/ask)Ask about this study:[🛡️Use Disorder](https://cedclinic.com/ask)[💢Pain](https://cedclinic.com/ask)[🧠Anxiety and Mood](https://cedclinic.com/ask)[🔎This study's limits](https://cedclinic.com/ask) Evidence Interpretation Guide ## How to Interpret This Cannabis News & Regulatory Digest Understanding registry data requires evaluating trial phases, therapeutic intent, and specific study populations. ### Three Rules for Critical Reading **Distinguish Trial Phases**Phase 1 studies measure acute physiological responses in tightly controlled settings, whereas Phase 3 trials evaluate broad clinical efficacy and safety across diverse clinical populations. **Account for Biological Variables**Sex differences alter cannabinoid receptor density, metabolic rate, and tissue distribution, making sex-stratified data essential for accurate dosing. **Evaluate Digital Tools Realistically**Pilot studies on mobile applications confirm user engagement and early feasibility, but long-term behavioral change requires extended observation and clinical support. Key Evaluation Question How do clinical protocols balance physiological symptom relief with long-term behavioral outcomes? The Patient Question How might my biological sex or daily habits affect my personal response to cannabinoid therapy or withdrawal management? The Bottom Line Rigorous clinical research advances patient safety by combining biological dosing precision with structured support tools. CED Perspective Lens ## CED Perspective Lens: Eight Viewpoints on These Updates Why these developments matter across clinical, patient, safety, and policy perspectives Lens OverviewEight distinct clinical and regulatory perspectives on Clinical Trial: An App to Reduce Cannabis Use. #### Understanding Individual Biological Factors and Support Tools Patients navigating cannabis therapies often encounter inconsistent advice regarding dosing and side effects. Recognizing that men and women react differently to identical doses helps individuals feel more confident during initial titration. Understanding that biological sex influences pain relief and sensitivity allows patients to work closely with their care team to customize daily routines safely. For individuals seeking to reduce or stop daily cannabis use, structured assistance makes a substantial difference. Having access to user-friendly smartphone tools alongside medical guidance provides constant support during challenging moments. Patients can track their progress, identify personal triggers, and navigate withdrawal symptoms without feeling overwhelmed or unassisted. Lens takeawayBiological factors and digital tools empower patients to manage cannabinoid therapies and cessation goals effectively. #### Translating Sex-Specific Dosing and Withdrawal Protocols Clinicians require evidence-based parameters to guide patient care effectively. Incorporating biological sex into initial dosing decisions reduces early treatment failures and adverse events. Recognizing sex-dependent differences in cannabinoid metabolism allows prescribers to refine starting doses and titration steps. This helps patients reach therapeutic windows safely without experiencing uncomfortable psychoactive responses. When managing cannabis use disorder, clinicians benefit from having structured withdrawal protocols. Combining emerging medical interventions with digital tracking applications provides a comprehensive approach to patient care. Monitoring withdrawal scores and providing continuous behavioral support improves patient retention during critical early abstinence phases. Lens takeawaySex-informed dosing and structured withdrawal management protocols enhance clinical efficacy and support patient retention. #### Prioritizing Biological Precision and Withdrawal Risk Mitigation Safety protocols in cannabinoid medicine must account for individual physiological differences and withdrawal dynamics. Controlled studies demonstrate that acute cannabinoid responses vary significantly between sexes, requiring tailored safety boundaries during initial administration. Unmonitored, rapid dosage escalations increase risk, particularly for individuals with higher baseline sensitivity or lower metabolic tolerance rates. Managing abrupt cessation presents distinct safety considerations, as unmanaged withdrawal symptoms can cause severe sleep disturbances and psychological distress. Utilizing validated pharmacological tools and digital tracking helps stabilize patients during acute abstinence. Systematic monitoring reduces adverse outcomes and prevents secondary complications associated with abrupt treatment discontinuation. Lens takeawayTailored dosing and active withdrawal monitoring are fundamental requirements for maintaining patient safety. #### Aligning Clinical Evidence with Regulatory Frameworks Healthcare policy frameworks must adapt to expanding research on cannabinoid science and substance use disorders. Regulatory agencies rely on Phase 1 safety data and Phase 3 clinical efficacy trials to establish formal guidelines for therapeutic products. Supporting rigorous clinical trials ensures that public health policies reflect concrete empirical outcomes rather than anecdotal observations. Policy initiatives supporting digital health tools expand access to evidence-based substance use interventions. Standardizing reimbursement pathways for mobile behavior-change applications lowers barriers for underserved populations. Combining formal drug approval pathways with digital health infrastructure creates scalable support systems for managing cannabis use disorder across diverse communities. Lens takeawayEvidence-based regulation and digital health coverage expand safe access and clinical support for cannabis consumers. #### Advancing Methodological Rigor in Cannabinoid Trials Translational research bridges fundamental biological mechanisms with practical clinical applications. Investigating sex-dependent pharmacodynamics isolated in controlled laboratory trials advances understanding of endocannabinoid signaling mechanisms. These detailed mechanistic findings inform the design of subsequent clinical trials so secondary variables are properly accounted for in larger human studies. Advancing targeted therapeutics for cannabis withdrawal requires multi-center Phase 3 trial designs that compare novel formulations against established active controls. Concurrently, behavioral researchers evaluate how mobile applications engage participants in daily health tracking. Integrating pharmacological and behavioral research domains creates comprehensive models for managing complex substance use disorders. Lens takeawayRigorous clinical research integrates biological mechanism discovery with practical behavioral intervention design. #### Evaluating Methodological Limits and Data Applicability Critical analysis requires examining study limitations before applying findings to broad populations. Small Phase 1 laboratory cohorts under controlled acute conditions do not reflect the complex reality of chronic, multi-cannabinoid consumption. Clinicians must avoid over-extrapolating early laboratory findings to everyday commercial cannabis products with varied terpene and cannabinoid profiles. Similarly, pilot trials for mobile health apps often report enthusiastic initial user engagement, but long-term compliance routinely declines after active trial monitoring ends. Furthermore, self-reported data on cannabis reduction carries inherent reporting biases. Demonstrating long-term clinical utility requires randomized controlled trials with objective biological verification of abstinence. Lens takeawayObjective evaluation demands long-term trials with biological verification rather than reliance on short pilot data. #### Supporting Family Members Through Treatment and Cessation Caregivers supporting family members using medical cannabis or seeking reduction support benefit from clear, objective guidance. Understanding that men and women experience different side effect profiles helps caregivers recognize early signs of sensitivity or tolerance changes. This knowledge enables families to communicate effectively with medical providers during treatment updates. During periods of planned cannabis reduction or cessation, caregivers often observe withdrawal challenges firsthand. Having access to monitored pharmaceutical options and user-friendly tracking apps provides structured routine support. Caregivers can assist with symptom tracking and app engagement, creating a supportive home environment during critical transition periods. Lens takeawayInformed caregivers play a vital role in supporting safe dosing adjustments and structured cessation routines. #### Integrating Biological Stratification and Comprehensive Cessation Care Recent clinical trial developments emphasize the importance of individualized cannabinoid management. Biological sex significantly influences analgesic responses and side effect susceptibility, necessitating thoughtful dosing frameworks tailored to the individual. Incorporating sex-specific considerations improves overall safety and therapeutic success for individuals using medical cannabis formulations. Addressing cannabis use disorder requires a modern, multi-modal treatment strategy combining medical and digital tools. Controlled trials testing pharmaceutical withdrawal agents alongside smartphone interventions demonstrate a comprehensive approach to cessation care. Clinicians and patients possess expanding resources to manage both biological sensitivities and daily behavioral patterns. Lens takeawayCombining personalized dosing frameworks with multi-modal cessation tools transforms modern clinical cannabis management. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care [Dr. Benjamin Caplan, MD](https://cedclinic.com/drcaplan/) Board-Certified Family Physician • Cannabinoid Specialist • 350k+ Patients Evaluated A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Meet Dr. Caplan (CV)](https://cedclinic.com/drcaplan/) [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](http://CEDclinic.com/book) [Cannabis Care](http://CEDclinic.com/book) [https://cedclinic.com/drcaplan/](https://cedclinic.com/drcaplan/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Clinical+Trial%3A+An+App+to+Reduce+Cannabis+Use+Among+Emerging+Adults&url=https%3A%2F%2Fcedclinic.com%2Fced-sex-differences-targeted-therapeutics-and-dig-2026-10-27%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fced-sex-differences-targeted-therapeutics-and-dig-2026-10-27%2F) [BlueSky](https://bsky.app/intent/compose?text=Clinical+Trial%3A+An+App+to+Reduce+Cannabis+Use+Among+Emerging+Adults%20https%3A%2F%2Fcedclinic.com%2Fced-sex-differences-targeted-therapeutics-and-dig-2026-10-27%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Primary Sources: University of California, Los Angeles, PleoPharma, Inc., University of Michigan](https://clinicaltrials.gov/study/NCT04385082) Related Reading at CED ClinicContinue exploring the evidence[Cannabis Use Disorder Is Rising Among US Adults](https://cedclinic.com/cannabis-use-disorder-rising-us-adults-2026/) More on this topic: Epidemiological evaluation of diagnostic trends, screening tools, and evidence-based patient counseling. [More on this topic: CUD trends & screening](https://cedclinic.com/cannabis-use-disorder-rising-us-adults-2026/)[PP-01 for Cannabis Withdrawal: What a 14-Person Trial Found](https://cedclinic.com/pp01-cannabis-withdrawal-proof-of-concept/) More on this topic: Clinical trial data evaluating pharmacological interventions and supportive care for cannabis withdrawal. [More on this topic: Withdrawal management](https://cedclinic.com/pp01-cannabis-withdrawal-proof-of-concept/)[Adolescent Cannabis Use and Its Impact on Cognitive Development: Insights from the ABCD Study](https://cedclinic.com/adolescent-cannabis-use-cognitive-development-risk/) More on this topic: Long-term ABCD study findings on adolescent brain development, executive function, and early cannabis susceptibility. [More on this topic: Adolescent brain health](https://cedclinic.com/adolescent-cannabis-use-cognitive-development-risk/) ## Frequently Asked Questions What is covered in this cannabis news & regulatory digest? This edition reviews 3 verified developments across cannabis policy, regulatory oversight, and clinical science. How are stories selected for CED digests? Stories are curated from official primary sources, government agency dockets, and peer-reviewed journals, focusing on practical relevance for patients and clinicians. Do preliminary reports establish medical efficacy? No. Observational reports, preprints, and regulatory filings describe emerging trends and require formal clinical trials before treatment efficacy can be claimed. How should clinicians use these updates? Clinicians can use these updates to understand patient questions, stay current with state regulations, and maintain evidence-informed counseling. Where can readers find Dr. Caplan's clinical insights? Dr. Caplan provides comprehensive clinical perspectives, patient consultations, and educational resources at CEDclinic.com. Why are multi-topic digests published instead of single stories? Digests group related updates together to provide a broader thematic overview while preserving important nuances and methodological limits. What is the primary role of laboratory testing in cannabis policy? Laboratory testing verifies cannabinoid potency and screens for harmful contaminants like heavy metals, pesticides, and molds to protect consumer health. How do state regulatory milestones impact patient access? Administrative milestones establish the licensing rules, product categories, and retail standards that determine how and where registered patients obtain care. What precautions should families take with medical cannabis at home? Families should keep all medical cannabis products securely locked in child-resistant containers and clearly labeled to avoid accidental exposure. How often does CED Clinic publish clinical and policy updates? CED Clinic publishes regular morning, afternoon, and evening evidence reviews and news digests to keep the community informed. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).